Exelixis, Inc. (EXEL)
Chart Events
Performance Outlook
| Previous Close | 20.33 |
| Open | 20.33 |
| Bid | 19.85 x 3100 |
| Ask | 20.42 x 4000 |
| Day's Range | 20.05 - 20.48 |
| 52 Week Range | 16.19 - 25.77 |
| Volume | 969,264 |
| Avg. Volume | 2,502,585 |
| Market Cap | 6.33B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | 98.54 |
| EPS (TTM) | 0.20 |
| Earnings Date | Nov 03, 2021 - Nov 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.77 |
- Zacks
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.
- Zacks
Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer
Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.
- Business Wire
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
ALAMEDA, Calif., September 20, 2021--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX® (cabozantinib) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC). Following a previous announcement that the trial met one of the two primary endpoints of significant improvement versus placebo in progression-free survival (PFS) assessed by blinded independent radiology committee (BIRC; p<0.000
